FY2025 EPS Estimates for FDMT Increased by Cantor Fitzgerald

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) – Cantor Fitzgerald increased their FY2025 earnings estimates for shares of 4D Molecular Therapeutics in a report released on Tuesday, March 4th. Cantor Fitzgerald analyst J. Schimmer now anticipates that the company will post earnings of ($3.22) per share for the year, up from their previous estimate of ($3.46). The consensus estimate for 4D Molecular Therapeutics’ current full-year earnings is ($2.84) per share.

Several other analysts have also recently issued reports on FDMT. Weiss Ratings reissued a “sell (d-)” rating on shares of 4D Molecular Therapeutics in a research note on Friday. HC Wainwright reissued a “buy” rating and set a $36.00 price target on shares of 4D Molecular Therapeutics in a research report on Monday, March 3rd. Royal Bank of Canada cut their price objective on 4D Molecular Therapeutics from $39.00 to $35.00 and set an “outperform” rating on the stock in a report on Monday, March 3rd. Bank of America decreased their target price on 4D Molecular Therapeutics from $79.00 to $46.00 and set a “buy” rating for the company in a report on Wednesday, December 18th. Finally, Morgan Stanley cut their price target on shares of 4D Molecular Therapeutics from $8.00 to $6.00 and set an “underweight” rating on the stock in a report on Monday, January 13th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and seven have given a buy rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $31.38.

4D Molecular Therapeutics Stock Performance

FDMT stock opened at $4.07 on Thursday. The stock has a market capitalization of $188.45 million, a P/E ratio of -1.43 and a beta of 2.83. 4D Molecular Therapeutics has a one year low of $3.92 and a one year high of $36.25. The company has a 50 day moving average price of $5.08 and a two-hundred day moving average price of $8.34.

4D Molecular Therapeutics (NASDAQ:FDMT) last released its earnings results on Friday, February 28th. The company reported ($0.90) EPS for the quarter, missing the consensus estimate of ($0.80) by ($0.10).

Institutional Investors Weigh In On 4D Molecular Therapeutics

A number of large investors have recently modified their holdings of FDMT. Millennium Management LLC grew its stake in shares of 4D Molecular Therapeutics by 1,607.1% in the fourth quarter. Millennium Management LLC now owns 1,420,723 shares of the company’s stock valued at $7,913,000 after buying an additional 1,337,497 shares in the last quarter. Braidwell LP grew its stake in shares of 4D Molecular Therapeutics by 231.7% in the third quarter. Braidwell LP now owns 1,225,448 shares of the company’s stock valued at $13,247,000 after buying an additional 855,990 shares in the last quarter. JPMorgan Chase & Co. grew its stake in 4D Molecular Therapeutics by 159.5% during the 4th quarter. JPMorgan Chase & Co. now owns 820,069 shares of the company’s stock valued at $4,568,000 after purchasing an additional 504,086 shares in the last quarter. Norges Bank acquired a new stake in 4D Molecular Therapeutics during the 4th quarter valued at approximately $2,790,000. Finally, Cubist Systematic Strategies LLC raised its position in shares of 4D Molecular Therapeutics by 2,084.5% in the 4th quarter. Cubist Systematic Strategies LLC now owns 448,831 shares of the company’s stock valued at $2,500,000 after purchasing an additional 428,285 shares in the last quarter. Institutional investors and hedge funds own 99.27% of the company’s stock.

About 4D Molecular Therapeutics

4D Molecular Therapeutics, Inc, a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology.